Journal of Pharmaceutical and Biopharmaceutical Research https://www.syncsci.com/journal/JPBR <p><a title="Registered Journal" href="https://www.reviewercredits.com/user/j-pharm-biopharm-res" target="_blank" rel="noopener"><img class="journalreviewercredits" src="/journal/public/site/images/jasongong/Logo_ReviewerCredits-journal.jpg" alt="ReviewerCredits" align="right"></a><strong>Journal of Pharmaceutical and Biopharmaceutical Research (JPBR)</strong> (ISSN:2630-533X)&nbsp; is an open access, continuously published, international, refereed&nbsp; journal. The aim of the journal is to provide the authors a timely and peer reviewed process for evaluation and publication of their manuscripts. All articles submitted to JPBR will undergo a rigorous double-blind peer review, and all published articles can be downloaded and read for free. JPBR will pay wide attention to the trends in related fields and insist on publishing original research work of highest quality.</p> <p><strong>JPBR</strong> publishes high quality original research work, reviews, and short communications in the following areas:<br><strong>Pharmaceutical Sciences:<br></strong>• Pharmaceutics<br> • Pharmacology and Toxicology<br> • Medicinal Chemistry<br> • Physical Pharmacy<br> • Pharmaceutical Analysis<br> • Chromatography and Hyphenated Techniques<br> • Pharmacognosy and Phytochemistry<br> • Nanotechnology for Pharmaceutical Drug Formulations<br><strong>Biopharmaceutical Sciences:</strong> <br> • Biochemistry<br> • Biotechnology<br> • Molecular Biology<br> • Immunology and Microbiology</p> en-US <p>Authors contributing to&nbsp;<em>Journal of Pharmaceutical and Biopharmaceutical Research</em>&nbsp;agree to publish their articles under the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0">Creative Commons Attribution-Noncommercial 4.0 International License</a>, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear.</p> snowy.wang@syncsci.com (Snowy Wang) editor@syncsci.com (Alan Tan) Wed, 15 May 2024 10:05:30 +0800 OJS 3.1.1.0 http://blogs.law.harvard.edu/tech/rss 60 Blockchain technology for advanced therapy medicinal products: Applications in tracking, data sharing, and supply chain automation https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.004 <p>Advanced therapy medicinal products (ATMPs) like cell and gene therapies offer transformative treatment options for many diseases. However, coordinating the decentralized, patient-specific manufacturing of autologous ATMPs across multiple hospitals poses major supply chain challenges. This paper provides a comprehensive analysis of how blockchain technology can enhance decentralized ATMP manufacturing networks. First, background on ATMPs and complexities of decentralized production is reviewed. An overview of blockchain architecture, key attributes, and existing use cases then follows. The major opportunities for blockchain integration in ATMP manufacturing are discussed in depth, including tracking autologous products across locations, enabling data sharing between hospitals to power AI-based optimization, automating supply chain processes, and maintaining provenance records. Critical limitations around scalability, privacy, regulation, and adoption barriers are examined. Design considerations for developing blockchain ecosystems tailored to the unique ATMP environment are also explored. Blockchain shows immense promise for transforming visibility, coordination, automation, and data unification in decentralized ATMP manufacturing networks. Despite current challenges, blockchain is prepared to profoundly impact the advancement of personalized cell and gene therapies through enhanced supply chain instrumentation. This paper provides a comprehensive analysis of this emerging technological innovation and its applications to address critical needs in ATMP translation and manufacturing.</p> Cristobal Aguilar-Gallardo, Ana Bonora-Centelles Copyright (c) 2024 Cristobal Aguilar-Gallardo, Ana Bonora-Centelles https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.004 Tue, 18 Jun 2024 08:39:55 +0800 Anticonvulsant activities of the methanol crude extract and fractions of the leaf Solanum americanum (S.a.) in pentylenetetrazole and 4-amino pyridine induced seizure in white albino rats https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.003 <p>This research investigated the anticonvulsant effect of the crude extract and fractions of <em>Solanum americanum’s </em>(S.a.) leaves on seizures induced by pentylenetetrazole (PTZ) and 4- amino pyridinein albino rats to authenticate the use of the leaves in the treatment of epilepsy in South -Eastern Nigeria. The leaves of S.a were extracted with methanol and fractionated using n-hexane, ethyl acetate and methanol. The parameters observed were onset of convulsions in minutes, duration of clonic phase in minutes, percentage protection from seizures and mortality. The anticonvulsant tests were carried out using 60 (sixty) white albino rats (weighing 80-136 g) of both sexes, varying concentrations of both methanol extracts and fractions (12.5, 25.0, 50.0, 100 and 200 mg/kg b.w.) were administered to the rats after which convulsion were induced in the rats using 9.0 mg/kg of PTZ and 1.5 mg/kg 4-amino pyridine on different groups (35 and 25) of rats respectively. The results of the various groups were compared with the control group and significance was analyzed by one-way ANOVA. The acute toxicity test was conducted at a dose of 3000 mg/kg. At a peak dose of 200 mg/kg methanol crude extract, hexane and methanol fraction in PTZ model protected the animals from seizure at 89.30%, 100%, 100% but gave 80%, 80% and 60% protection from mortality respectively. Hexane fraction (12.5, 25, 50, 100 and 200 mg/kg) protected the rats against mortality at 20%, 40%, 60%, 60% and 80% respectively, while no anticonvulsant activities were detected in ethyl acetate fraction. Differences among the means and standard deviation was statisticall<strong>y</strong> significant at <em>P</em> &lt; 0.05.The acute toxicity test showed that the leaf of S.a. is non-toxic. The result obtained substantiated the use of the leaf of <em>Solanum americanum </em>ethnobotanically as anticonvulsant.</p> Rita Nwabiani, Adaora S. Ogbuagu, Isaac O. Okerulu Copyright (c) 2024 Rita Nwabiani, Adaora S. Ogbuagu, Isaac O. Okerulu https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.003 Fri, 31 May 2024 13:58:40 +0800 A big threat : Aflatoxin https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.002 <p>The past decade has witnessed a tremendous surge of interest in herbal medicines throughout the world. Aflatoxins are naturally occurring mycotoxins that are mainly produced by <em>Aspargillus flavus</em> and <em>Aspargillus parasiticus and </em>primarily contaminate food crops such as corn, groundnuts, and tree nuts as well as herbal medicinal plants in tropical and subtropical regions of the world. It is a lethal substance that intensely or at slower ingestion influences the strength of humans and animals. Aflatoxin study is vital for a safety perspective as they are extremely lethal and cancer-causing; to overcome the health effect of aflatoxins and for better assessment and standardization of herbal plant drugs. &nbsp;The investigation includes worldwide regulations on aflatoxins with their acceptable ranges in commodities. With more controls for adequate dimensions of aflatoxins set up, present-day analytical techniques have turned out to be very modern, capable of accomplishing results with high accuracy and precision, appropriate for administrative research centers and post-reap sample testing in developed countries.</p> Ritu Tiwari, Aanal Pandaya, Poornima Gulati, Aishwarya Chahuan Copyright (c) 2024 Ritu Tiwari, Aanal Pandaya, Poornima Gulati, Aishwarya Chahuan https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.002 Wed, 22 May 2024 09:26:20 +0800 Determination of pesticide residues and heavy metals in Adhatoda Vasaka Linn. https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.001 <p>Heavy metals and pesticide residue analysis plays an important role in the quality control of medicinal plants like Vasaka <em>(Adhatoda vasica).</em> Hence a study was conducted to determine heavy metals and pesticide residues in this medicinal herb, which is a highly useful commodity in the health system. The reliable, rapid and nontoxic sample preparation method like QuEChERS and analytical methods like GC-MS were proposed for the simultaneous determination of pesticide residues and Heavy metal detection was carried out by ICP-MS. In this study, the presence of organophosphorus and organochlorine pesticides like alachlor, heptachlor, heptachlor epoxide, aldrin, dieldrin, endrin, etc was checked but not detected. Heavy metals like Arsenic (As), Cadmium (Cd), Mercury (Hg) and Lead (Pb) are traced in samples about 2.3005 ppb, 0.799 ppb, 2.290 ppb and 10.204 ppb respectively in the present study.</p> Ritu Tiwari, Aishwarya Chauhan, Madhavi Patel, Komal Patel Copyright (c) 2024 Ritu Tiwari, Aishwarya Chauhan, Madhavi Patel, Komal Patel https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.02.001 Wed, 15 May 2024 10:05:08 +0800 TAAR1 as a new target for the treatment of bipolar disorder: Anti-manic and anti-depressant activity of the novel agonist PCC0105004 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.004 <p><strong>Background</strong>: Bipolar disorder (BD) is a deleterious psychiatric disorder, and the available pharmacotherapies have limited efficacy with significant side effects. Trace amine-associated receptor 1 (TAAR1) is an emerging drug target for neuropsychiatric disorders such as schizophrenia and substance user disorders. However, it is unknown whether TAAR1 is involved in the pathogenesis of BD. This study examined the effects and underlying mechanisms of a novel TAAR1 agonist, PCC0105004, in a rat model of ouabain (OUA)-induced BD.<br><strong>Methods</strong>: Intracerebroventricular (ICV) administration of OUA-induced BD model was established. The in vitro cell-based cAMP assay was used to examine TAAR1 agonism of PCC0105004. The receptor specificity of PCC0105004 was determined by an off-target panel assay that included radioligand binding and enzymatic assays. The effects of PCC0105004 on manic-like and depressive-like behaviors were evaluated in the rat BD model. TAAR1-mediated signaling and oxidative stress parameters were biochemically determined in the prefrontal cortex and the hippocampus of rats.<br><strong>Results</strong>: Western blotting revealed reduced TAAR1 expression level in the prefrontal cortex but unchanged in the hippocampus in model rats. PCC0105004, a TAAR1 agonist with the agonism EC<sub>50</sub> value of 0.06182 μM, attenuated the manic-like behaviors on the 7th day and the depressive-like behaviors on the 14th day at doses that did not affect locomotor activity in the BD rats. Mechanistically, PCC0105004 exerted its behavioral effects via the reduction of ROS damage through the phosphorylation activation of the TAAR1/Akt/GSK3β/BDNF signaling pathway.<br><strong>Conclusion</strong>: These results demonstrated the potential antimanic-like and antidepressant-like efficacy of a novel TAAR1 agonist PCC0105004 in rats and revealed its underlying molecular basis, which supports the possibility of TAAR1 agonists as candidate pharmacotherapeutics for BD.</p> Linyao Yu, Wei Zhang, Yaoqin Shi, Yingtian Zhang, Min Xu, Yang Xu, Chunmei Li, Jingwei Tian Copyright (c) 2024 Linyao Yu, Wei Zhang, Yaoqin Shi, Yingtian Zhang, Min Xu, Yang Xu, Chunmei Li, Jingwei Tian https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.004 Mon, 25 Mar 2024 10:02:31 +0800 A novel role of NK3 receptor signaling in bipolar disorder https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.003 <p><strong>Objective: </strong>Bipolar disorder (BD) affects more than 1% of the global population with limited therapeutic options. The neurokinin B (NKB)-neurokinin B receptor (NK3R) is involved in a variety of emotional activities. This study explored the role of NK3 receptor signaling in bipolar disorder.<br><strong>Materials and methods: </strong>In this study, a model of intracerebroventricular (ICV) administration of OUA-induced BD was used to investigate the possible role of NK3R signaling in BD. The involvement of NK3R in the expression of OUA-induced BD was assessed by genetically knocking down the NK3R-encoding <em>TACR3</em> gene with shRNA approach in the hippocampus and systemic administration of a NK3R antagonist ESN364,. Biochemical techniques were used to examine the NK3R-associated signaling changes and the oxidative stress parameters in the hippocampus of BD rats.<br><strong>Results: </strong>The NK3R expression level was elevated in the hippocampus BD rats. Both <em>TACR3</em> knockdown in the hippocampus and ESN364 treatment reversed the manic-like and depression-like behaviors in BD rats Inhibition of the NK3R signaling reversed oxidative stress-induced damage via upregulating the BDNF signaling pathway in the hippocampus.<br><strong>Conclusion: </strong>These results demonstrated that NK3R signaling plays a key role in the pathogenesis of BD and that pharmacological antagonist of NK3R such as ESN364 could represent a novel therapeutic strategy for the management of BD.</p> Wei Zhang, Linyao Yu, Yaoqin Shi, Yingtian Zhang, Min Xu, Yang Xu, Chunmei Li, Jingwei Tian Copyright (c) 2024 Wei Zhang, Linyao Yu, Yaoqin Shi, Yingtian Zhang, Min Xu, Yang Xu, Chunmei Li, Jingwei Tian https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.003 Thu, 14 Mar 2024 00:00:00 +0800 Network pharmacology-based prediction for therapeutic mechanism of FuYueKang Lotion on acute eczema https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.002 <p><strong>Objective</strong><strong>:</strong>&nbsp;Fuyuekang Lotion (FYKL) is an improved&nbsp;traditional Chinese medicine&nbsp;(TCM) prescription widely used to treat acute eczema (AE). However, the&nbsp;mechanism of action remains unclear. This study aimed to&nbsp;explore the therapeutic mechanism of FYKL&nbsp;in AE.<br><strong>Methods:</strong>&nbsp;We revealed&nbsp;the underlying mechanism by utilizing a network pharmacology approach, molecular docking studies, and in vitro verification. The active compounds in FYKL were identified, and their targets were predicted. These targets were subsequently mapped to a component-target interaction network, with their therapeutic mechanisms predicted through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking was used to verify protein-binding efficacy. Potential key targets of FYKL against AE were further confirmed via reverse transcription quantitative polymerase chain reaction (RT-qPCR).<br><strong>Results: </strong>The study identified 59 potential active compounds of FYKL, with quercetin, luteolin, and gallic acid suggested as critical active ingredients. Our findings suggest that these ingredients could exert their effects mainly by modulating the inflammatory immune response and promoting epidermal repair.&nbsp;FYKL was found to be a multi-target, multi-component drug that could potentially regulate the inflammatory immune response in AE through numerous pathways.<br><strong>Conclusions:</strong>&nbsp;The findings from this study provide a scientific basis for further research into the therapeutic effects and mechanisms of FYKL in treating AE, underscoring the potential of TCM in modern therapeutics.</p> Xiaowen Wen, Shaokang Cui, Minzhi Li, Yongping Zheng, Haoyou Xu Copyright (c) 2023 Xiaowen Wen, Shaokang Cui, Minzhi Li, Yongping Zheng, Haoyou Xu https://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.002 Wed, 01 Nov 2023 11:53:05 +0800 Exploring the mechanism of three herb pairs for the treatment of atherosclerosis through network pharmacology and molecular modeling https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.001 <p><strong>Background:</strong> Atherosclerosis (AS) is one of the leading causes of cardiovascular diseases. The traditional China herb pairs such as Huanglian-Gualou, Honghua-Taoren, and Suhexiang-Bingpian showed therapeutic effects on AS by clearing heat and resolving phlegm, invigorating blood and removing blood stasis, as well as aromatic resuscitation, respectively. However, the common and specific mechanisms of these pairs against the same disease are elusive.<br><strong>Objective:</strong> This study aimed to explore the molecular mechanisms of 3 herb pairs treating AS by network pharmacology, molecular modeling and mechanism experiments.<br><strong>Methods:</strong> The components and their corresponding targets of 3 herb pairs, as well as AS-related targets, were collected from multiple databases and literature. Then the protein-protein interaction network was built to identify the key components and targets associated with AS. The pathway enrichment analysis using KEGG was carried out for analyzing the common mechanisms of 3 herb pairs against AS. Finally, the binding modes of the key components and targets were analyzed by molecular docking and molecular dynamic simulation.<br><strong>Results:</strong> The PPI network indicated that the common targets of 3 herb pairs focused on four pathways, including regulated vascular shear stress, TNF, ARE-RAGE, and IL-17 pathways. The molecular docking analysis indicated that the key component quercetin showed highest docking score with PTGS2 in comparison to other targets. Molecular dynamics simulations revealed that quercetin stably anchored to the active pocket of PTGS2 by forming hydrogen bonds with Thr175, Asn351, and Trp356.<br><strong>Conclusion:</strong> The molecular mechanism of Huanglian-Gualou, Honghua-Taoren, and Suhexiang-Bingpian against AS was preliminarily expounded, and we wish to provide a theoretical instruction for clinical treatment of AS.</p> Minjun Wang Copyright (c) 2023 Minjun Wang http://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2023.01.001 Wed, 19 Apr 2023 16:45:35 +0800 LPM570065 ameliorates anxiety-like and depressive-like behaviors in CUMS rats through regulating DNA methylation in hippocampus https://www.syncsci.com/journal/JPBR/article/view/JPBR.2022.02.005 <p><strong>Objective</strong>: This study aims to analyze the effects and underlying mechanisms of LPM570065 on behavioral phenotypes in rats with generalized anxiety disorder (GAD).<br><strong>Methods</strong>: The chronic unpredictable mild stress (CUMS) rats were used to observe the results of LPM570065. Total 72 male Sprague Dawley rats were divided into control, vehicle (0.5% CMC-Na), LPM570065 (32 mg/kg) and diazepam (3 mg/kg) groups, 12 rats in each group. Anxiety-like behaviors of rats were observed by elevated zero maze test and novelty-suppressed feeding test. Depressive-like behaviors of rats were detected by forced swimming test. DNA methylation in hippocampi of rats were measured by reduced representation bisulfite sequencing (RRBS). In hippocampi of rats, expressions of DNA methyltransferase (DNMT) 1 and DNMT3a proteins were measured by western blot, and density of dendritic spines was observed by Golgi staining.<br><strong>Results</strong>: Compared with the control group, the weights of rats were obviously decreased (p &lt; 0.001) and the rats showed anxiety-like and depressive-like behaviors (p &lt; 0.001) in the vehicle group. Compared with the vehicle group, the weights of rats were significantly increased (p &lt; 0.001) and the anxiety-like and depressive-like behaviors were improved (p &lt; 0.001) in the LPM570065 group. The results of RRBS showed that there were 49964 promoters showed hypermethylation in the LPM570065 treatment rats contrasted to the vehicle treatment rats. In addition, these promoters were enriched in signal transduction and immune function. Furthermore, the expressions of DNMT1 and DNMT3a were significantly decreased, the density of dendritic spines was significantly increased in hippocampi of LPM570065 treatment rats compared with the vehicle treatment rats.<br><strong>Conclusions</strong>: LPM570065 ameliorates anxiety-like and depressive-like behaviors in CUMS rats, and its mechanism is possible associated with downregulating DNA methylation in hippocampus.</p> Shengmin Ji, Chunmei Li, Wei Zhang, Linyao Yu, Yue Yang, Yaoqin Shi, Hongbo Wang, Jingwei Tian Copyright (c) 2023 Shengmin Ji, Chunmei Li, Wei Zhang, Linyao Yu, Yue Yang, Yaoqin Shi, Hongbo Wang, Jingwei Tian http://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2022.02.005 Mon, 17 Apr 2023 15:55:48 +0800 (E)-2-Benzylidenecyclanones: Part XVII. An LC-MS study of microsomal transformation reactions of (E)-2-[(4'-methoxyphenyl)methylene]-benzosuberon-1-one: A cyclic chalcone analog https://www.syncsci.com/journal/JPBR/article/view/JPBR.2022.02.004 <p>Biotransformation of the antiproliferative (<em>E</em>)-2-[(4’-methoxyphenyl)methylene]-benzosuberon-1-one (<strong>2c</strong>) was studied using rat liver microsomes. As a result of the CYP-catalyzed transformations, one monooxygenated (<strong>2c+O</strong>) and the demethylated (<strong>2c-CH<sub>2</sub></strong>) metabolites were identified by HPLC-MS. (<em>E</em>)-2-[(4’-methoxyphenyl)methylene]-benzosuberon-1-ol, the expected product of rat liver microsomal carbonyl reductase, was not found in the incubates. Microsomal GST-catalyzed reaction of the compound resulted in formation of diastereomeric GST-conjugates. Under the present HPLC conditions, the diastereomeric adducts were separated into two chromatographic peaks (<strong>2c-GSH-1</strong> and <strong>2c-GSH-2</strong>).</p> Fatemeh Kenari, Szilárd Molnár, Zoltán Pintér, Sobhan Bitaraf, Pál Perjési Copyright (c) 2023 Fatemeh Kenari, Szilárd Molnár, Zoltán Pintér, Sobhan Bitaraf, Pál Perjési http://creativecommons.org/licenses/by-nc/4.0 https://www.syncsci.com/journal/JPBR/article/view/JPBR.2022.02.004 Wed, 22 Mar 2023 13:53:43 +0800